PK-guided pazopanib dosing.
- Conditions
- cancerefficacytoxicitypazopanibkankermaligniteitbijwerkingeneffectpazopanib
- Registration Number
- NL-OMON28938
- Lead Sponsor
- Antoni van Leeuwenhoek, Amsterdam
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 30
Inclusion Criteria
1. Subjects must provide written informed consent prior to performance of study-specific procedures or assessments and must be willing to comply with treatment and follow up.
Note: Procedures conducted as part of the subject’s routine clinical management (e.g., blood count, imaging study such as bone scan) and obtained prior to signing of informed consent may be utilized for screening or baseline purposes provided these procedures are conducted as specified in the protocol;
Exclusion Criteria
1. Central nervous system (CNS) metastases at baseline, with the exception of those subjects who have previously-treated CNS metastases (surgery ± radiotherapy, radiosurgery, or gamma knife) and who meet both of the following criteria:
A. Are asymptomatic;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine the safety and feasibility of PK guided dosing of pazopanib.
- Secondary Outcome Measures
Name Time Method 1. Evaluation of the dried blood spot procedure;<br /><br>2. To determine the objective response rate (according RECIST 1.1);<br /><br>3. To determine the time to tumor progression and progression free survival.